Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PAION AG
Pipeline is concentrated around Phase II, but sponsors have a few chances to see how FDA handles its ‘foundational constructs’ for psychedelic drugs, led by Lykos’ pending NDA for PTSD and Compass Pathways’ Phase III synthetic psilocybin COMP360 for treatment-resistant depression.
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.
Medtech Insight's News We're Watching highlights medtech industry developments we are following: Intuitive announced an FDA filing for its da Vinci 5 surgical robot; Roche hits at CGM plans; Abbott launches a new smaller rechargeable deep brain stimulator; CroiValve starts transcatheter tricuspid valve trial; ReWalk rebrands as Lifeward; and more news you may have missed.
Japan has announced the latest evaluation results under its cost effectiveness assessment scheme. But how does it work and how much have prices been revised so far under the four-year-old program following discussions between pharma firms and authorities?
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- CeNeS Pharmaceuticals plc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.